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TORC2 is a major transcriptional coactivator for
hepatic glucose production. Insulin impedes gluco-
neogenesis by inhibiting TORC2 via SIK2-dependent
phosphorylation at Ser171. Interruption of this
process greatly perturbs hepatic glucose metabo-
lism, thus promoting hyperglycemia in rodents.
Here, we show that hyperactivation of TORC2 would
exacerbate insulin resistance by enhancing expres-
sion of LIPIN1, a mammalian phosphatidic acid
phosphatase for diacylglycerol (DAG) synthesis.
Diet-induced or genetic obesity increases LIPIN1
expression in mouse liver, and TORC2 is responsible
for its transcriptional activation. While overexpres-
sion of LIPIN1 disturbs hepatic insulin signaling,
knockdown of LIPIN1 ameliorates hyperglycemia
and insulin resistance by reducing DAG and PKC3
activity in db/db mice. Finally, TORC2-mediated
insulin resistance is partially rescued by concomitant
knockdown of LIPIN1, confirming the critical role of
LIPIN1 in the perturbation of hepatic insulin
signaling. These data propose that dysregulation of
TORC2 would further exaggerate insulin resistance
and promote type 2 diabetes in a LIPIN1-dependent
manner.
INTRODUCTION
Insulin resistance is a major predicament for the development of
type 2 diabetes. Increased infusion of free fatty acids into the
peripheral tissues due to the atherogenic diets or obesity directs
to the accumulation of intracellular free fatty acids, which then
leads to the generation of various second messengers for
signaling cascades, including diacylglycerol (DAG), a major acti-
vator for protein kinase C (PKC) families (Savage et al., 2007).
Among familymembers,PKC3 is known tobe involved in reducing240 Cell Metabolism 9, 240–251, March 4, 2009 ª2009 Elsevier Inc.insulin receptor (IR) kinase activity, thus inhibiting insulin-
mediated signaling cascades in liver (Samuel et al., 2004, 2007).
Previously identified as a gene product that is responsible for
the pathophysiology of fld mice, which show occurrence of
neonatal fatty liver that is accompanied by hypertriglyceridemia
and lipodystrophy phenotypes, LIPIN1 is later shown to be
involved in various pathways in lipid metabolism in diverse cell
types such as liver, adipose tissues, muscle, and neuronal cells
(Finck et al., 2006; Peterfy et al., 2001, 2005; Phan et al., 2004;
Phan and Reue, 2005; Reue and Zhang, 2008; Verheijen et al.,
2003). Depletion of LIPIN1 gene in preadipocytes delays the fat
cell differentiation, and fldmice that lack expression of functional
LIPIN1 display lipodystrophy-associated insulin resistance,
perhaps due to the lack of adipokine generation, showing the
importance of adipose-specific LIPIN1 function in lipid homeo-
stasis and systemic insulin signaling. On the other hand,
muscle-specific LIPIN1 transgenic mice show insulin resistance
and obesity phenotypes, suggesting the presence of differential
functions of LIPIN1 in different cell types. The role of LIPIN1 in
liver is somewhat more complicated. LIPIN1 appears to function
as a coactivator for PPARa/PGC-1a to transcriptionally regulate
fatty acid oxidation gene expression. At the same time, two
recent reports suggest contradicting results regarding functions
of LIPIN1 in the regulation of triglyceride synthesis and VLDL
secretion, depending on the systems utilized (Chen et al.,
2008; Khalil, 2009). The presence of other isoforms, LIPIN2
and LIPIN3, makes it hard to determine the sole contribution of
LIPIN1 in hepatic lipid metabolism (Reue and Dwyer, 2008).
Surprisingly, LIPIN1 is later identified as a cytosolic phosphatidic
acid phosphatase (PAP) that would generate DAG in response to
increase in intracellular free fatty acid levels (Carman and Han,
2006; Donkor et al., 2007; Han et al., 2006, 2007; Reue and
Zhang, 2008). The PAP function of LIPIN1 could potentially link
this protein with free fatty acid-induced perturbation of insulin
signaling that is observed in muscle-specific LIPIN1 transgenic
mice (Phan and Reue, 2005).
TORC2 is a major transcriptional coregulator for hepatic
glucose output in response to fasting in mammals (Koo et al.,
2005). While fasting triggers a rapid dephosphorylation and
nuclear entry of TORC2 to promote hepatic gluconeogenesis,
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the activity of inhibitory serine/threonine kinase SIK2 to reverse
the process by phosphorylating Ser171 residue of TORC2,
resulting in the retention of this factor in the cytoplasm in associ-
ation with 14-3-3 proteins (Dentin et al., 2007; Screaton et al.,
2004). During insulin-resistant conditions, however, TORC2
remains in the nucleus and is actively involved in coactivating
CREB-target gluconeogenic gene expression, in part due to
the inactivation of AKT-mediated SIK2, which results in hypergly-
cemia that would further exacerbate the insulin-resistant pheno-
type and ultimately bring about the type 2 diabetes.
Here, we report that TORC2 transcriptionally activates LIPIN1
expression during fasting and insulin-resistant conditions in
mouse liver. Overexpression of LIPIN1 in primary hepatocytes
indeed increases DAG production and results in inactivation of
AKT due to the activation of PKC3. Furthermore, adenovirus-
mediated knockdown of hepatic LIPIN1 in diabetic db/db mice
greatly alleviates hyperglycemia as well as hepatic insulin resis-
tance. These data support that TORC2-mediated induction of
LIPIN1 expression during insulin resistance would greatly
contribute to the further exacerbation of hyperglycemia and
the progression of type 2 diabetes.
RESULTS
S171A TORC2 Promotes Hepatic Insulin Resistance
As reported previously, Ser171 residue of TORC2 is targeted by
AMPK and AMPK-related kinases, including SIK kinases, and is
critical for determining its cellular localization (Koo et al., 2005;
Shaw et al., 2005). Mutation of this residue into alanine results
in constant nuclear localization of TORC2, which leads to the
unregulated activation of TORC2/CREB target genes. Indeed,
mice injected with adenovirus for Ser171 to alanine mutant
TORC2 (S171A TORC2) show higher blood glucose levels as
well as increased expression of gluconeogenic genes (Figures
1A and 1C) relative to mice with GFP control adenovirus injec-
tion. Unexpectedly, S171A TORC2 mice show impaired glucose
tolerance compared with GFPmice (Figure 1B). We would spec-
ulate this is due to either the increased gluconeogenic/
decreased glycolytic gene expression or the increased TORC2
target gene expression in S171A mouse that would potentially
perturb insulin signaling in this setting.
LIPIN1 Is a Transcriptional Target of TORC2 in Liver
To gain a further insight into the nature of this phenomenon, we
performed microarray analysis using RNAs from mouse liver
infected with either TORC2 RNAi adenovirus or US control
RNAi adenovirus. As shown previously, several TORC2/CREB
target genes in the gluconeogenesis are downregulated by
TORC2 knockdown in microarray analysis (Table 1) and are
confirmed by quantitative PCR (Q-PCR) (Figure 1E). Knockdown
of TORC2 does not promote changes in expression of several
glycolytic enzyme genes. Surprisingly, we noticed a change in
gene expression levels of LIPIN1, a member of mammalian
PAP families, by TORC2 knockdown. Fasting and either diet-
induced or genetic insulin resistance in mouse enhance hepatic
LIPIN1 expression (Figures 2A, 2B, and S1–S4), while SIK
expression greatly inhibits it (Figures S5–S7), showing similar
regulatory patterns with gluconeogenic PEPCK gene in theseCsettings. Indeed, we were able to confirm the increased expres-
sion of LIPIN1, but not of LIPIN2 or 3, by S171A TORC2 infection
in mouse liver or in primary hepatocytes (Figures 1C, 1D, and
2C). Furthermore, expression of LIPIN1 is increased by TORC2
and inhibited by CREB inhibitor ACREB in primary hepatocytes,
further confirming that TORC2/CREB might regulate LIPIN1
expression in liver (data not shown). To verify whether TORC2/
CREB would regulate LIPIN1 expression at the transcriptional
level, we obtained LIPIN1 promoter from mouse genomic DNA
and performed transient transfection assays in HepG2 cells.
We chose to utilize sequences upstream of exon 1b as a hepatic
promoter for LIPIN1, since exon 1b appears to be selectively
expressed over exon 1a in hepatocytes. Moreover, hepatic
LIPIN1 transcript with exon 1b is regulated by fasting or
insulin–resistance mousemodels, as shown by RT-PCR analysis
using differential exon-specific primers (Figure S8). Interestingly,
LIPIN1 promoter is upregulated by TORC2 cotransfection in the
presence of PKA, and TORC2-/cAMP-responsive region is local-
ized 85 to +56 from the putative transcriptional start site (Fig-
ures 2D and 2E). TORC2 occupies promoter regions of several
CREB target genes, such as PEPCK or G6Pase, and the occu-
pancy of TORC2 on the LIPIN1 promoter is also confirmed by
chromatin immunoprecipitation assay in mouse primary hepato-
cytes, further confirming that TORC2 regulates LIPIN1 expres-
sion at the transcriptional level in vivo (Figure 2F).
LIPIN1 Expression Increases DAG Production
and Inhibits Insulin Signaling in Primary Hepatocytes
Increased production of DAG is linked to obesity-related insulin
resistance in peripheral tissues (Samuel et al., 2004, 2007;
Savage et al., 2007). Since LIPIN1 was previously reported as
a mammalian cytosolic PAP in other cell types, we wanted to
verify whether this protein functions similarly in liver. Adeno-
virus-mediated overexpression of wild-type (WT) LIPIN1 or
LIPIN2 induces DAG production in response to palmitate treat-
ment, while LIPIN1 with mutations in previously defined phos-
phatase active sites does not promote such events in primary
hepatocytes (Figures 3A and S9). In accordance with increased
DAG production by WT LIPIN1, Ser729 phosphorylation of
PKC3, a major noncanonical PKC isoform in liver, is much
more pronounced with WT LIPIN1-infected cells compared
with cells infected with GFP or PAP mutant LIPIN1 in response
to phosphatidic acid (PA) treatments, a direct substrate for
LIPIN1 (Figure 3C). In addition, Ser473 phosphorylation of AKT
is accordingly more dramatically reduced in WT LIPIN1 infected
cells with treatment of PA (over 34-fold in WT LIPIN1 versus less
than 10-fold in PAP mutant LIPIN1) (Figures 3B and 3C), sug-
gesting that increased expression of LIPIN1 in the abundance
of its substrates could promote insulin resistance in liver. To
test whether the disturbance of insulin signaling may affect glu-
coneogenic gene expression, we infected primary hepatocytes
with GFP control, WT LIPIN1, or PAP mutant LIPIN1 adenovi-
ruses in the absence or in the presence of PA/insulin. Expression
of either WT or PAP mutant LIPIN1 does not promote significant
changes in PGC-1a or PEPCKmRNA levels in the absence or in
the presence of PA without insulin treatment (Figure 3D). As
expected, short-term treatment of insulin (4 hr) dramatically
reduces mRNA levels of both genes. Indeed, PA treatment
slightly blocks insulin-mediated inhibition of PEPCK geneell Metabolism 9, 240–251, March 4, 2009 ª2009 Elsevier Inc. 241
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expression of WT but not PAP mutant LIPIN1. These data
suggest that LIPIN1 may not directly regulate gluconeogenic
expression at the transcriptional level, but block insulin-depen-
dent regulation of these genes by disturbing hepatic insulin
signaling via its DAG-producing activity.
Knockdown of Hepatic LIPIN1 Improves Diabetic
Conditions in db/db Mice
To verify the functional significance of LIPIN1 in the insulin resis-
tance in vivo, we prepared adenovirus for LIPIN1 shRNA and
injected it into the db/db diabetic mice, widely utilized rodent
models displaying peripheral insulin resistance. Interestingly,
Figure 1. TORC2 Promotes Elevations in Blood Glucose Levels and Glucose Intolerance
(A) Sixteen hour fasting glucose levels in mice expressing Ad-GFP or Ad-S171A TORC2 (*p < 0.05; n = 3).
(B) Glucose tolerance test (GTT) of Ad-GFP and Ad-S171A TORC2 mice (*p < 0.05; **p < 0.01; n = 3).
(C) Effects of Ad-S171A TORC2 infection on LIPIN1 gene expression; Q-PCR analysis of hepatic LIPIN1, TORC2, PEPCK, and G6Pase expression using hepatic
RNAs from Ad-GFP or Ad-S171A TORC2-injected mice (*p < 0.01; n = 3).
(D) Western blot analysis of hepatic TORC2 and LIPIN1 levels in mice infected with Ad-GFP or Ad-S171A TORC2 virus. HA-TORC2 levels are shown on the top
panel.
(E) Effects of TORC2 knockdown on LIPIN1 gene expression; Q-PCR analysis of hepatic LIPIN1, TORC2, PEPCK, and G6Pase expression using hepatic RNAs
from Ad-US control RNAi adenovirus or Ad-TORC2 RNAi virus-injected mice (*p < 0.01; n = 3). Data in (A)–(C) and (E) represent mean ± SD.242 Cell Metabolism 9, 240–251, March 4, 2009 ª2009 Elsevier Inc.
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Hepatic LIPIN1 Promotes FFA-Induced Insulin ResistanceLIPIN1 expression is highly induced in livers of diabetic mice, as
shown in Figure 2B and in the previous report (Finck et al., 2006).
Knockdown of hepatic LIPIN1 is verified by Q-PCR as well as
western blot analysis (Figures 4C, 4D, and 5A). Surprisingly,
LIPIN1 knockdown greatly lowers blood glucose level that is
associated with reduction in key gluconeogenic gene expression
(Figures 4A, 5A, and S10). Moreover, intraperitoneal glucose
tolerance test (GTT) reveals the improvement in glucose intoler-
ance of db/dbmice with LIPIN1 knockdown compared withmice
with control viruses, suggesting a notion of increased hepatic
insulin sensitivity with reduced hepatic LIPIN1 expression
(Figure 4B). Indeed, tyrosine phosphorylation of IR, as well as
serine phosphorylation of AKT, FOXO1, and GSK3b, is greatly
increased by LIPIN1 knockdown both in basal and insulin-
induced conditions (Figures 4C, 4D, and S11). While there are
no changes in plasma TAG andNEFA levels (Figure S12), hepatic
DAG and TAG levels are greatly reduced with Ad-LIPIN1 RNAi
infection (Figure 5B). Moreover, phosphorylation level of PKC3
is also significantly diminished (Figures 4C and 4D), further
corroborating the notion that hepatic LIPIN1 knockdown
improves insulin sensitivity in insulin-resistant conditions. To
further evaluate the functional consequences of LIPIN1 defi-
ciency in insulin and glucose metabolism in vivo, we performed
the 140 min hyperinsulinemic-euglycemic clamp studies in
conscious db/db mice. Basal hepatic glucose production of
LIPIN1 knockdown mice tends to be lower than that of control
mice (p = 0.09) (Figure 5C). During the clamp periods, plasma
insulin was infused at a constant rate (30 pmol/kg/min) to raise
plasma insulin within a physiological range, and plasma glucose
was clamped at about 6.7 mM. Indeed, knockdown of LIPIN1
increases hepatic insulin sensitivity, as reflected by70%higher
suppression of endogenous glucose production from LIPIN1-
deficientmice compared to control groups (Figure 5C). However,
there are no significant differences in whole-body glucose
uptake, glycolysis, and glycogen synthesis between the two
groups (Figure 5E). Consistent with no changes in peripheral
insulin sensitivity other than that of liver, muscle glucose uptake
Table 1. Results of cDNA Microarray Data
Gene symbol Fold induction
shTORC2/US
LIPIN1* 0.733
LIPIN2 1.018
LIPIN3 1.131
G6pase* 0.478
PGC-1a* 0.809
PC 0.803
FBP1 0.702
GCK 1.023
PFK1 0.871
ADOLB 1.192
PFKFB2 0.923
G6pase, glucose-6-phosphatase; PGC-1a, peroxisome proliferator-acti-
vated receptor gamma coactivator 1 a; PC, pyruvate carboxylase; FBP1,
Fructose-1,6-bisphosphatase 1;. GCK, glucokinase; PFK1, liver-type
phosphofructokinase; ALDOB, aldolase B; PFKFB2, 6-phosphofructo-
2-kinase/fructose-2,6-bisphosphatase 2. n = 3, C57BL/6, liver.
*Confirmed by Q-PCR (Figure 1E).Cdoes not show differences between the two groups of mice
(Figure 5D).
LIPIN1 Knockdown Prevents S171A TORC2-Induced
Insulin Resistance
Finally, we wanted to confirm whether S171A TORC2-induced
glucose intolerance in mice is due to the increased expression
of LIPIN1. Thus, Ad-LIPIN1 RNAi virus was coinjected with
Ad-S171A TORC2 virus in normal mice and compared with
Ad-GFP + Ad-US groups and Ad-S171A TORC2 + Ad-US
groups. Ad-GFP + Ad-LIPIN1 RNAi group is not included, since
we did not observe changes in blood glucose or glucose toler-
ance with LIPIN1 knockdown only in WT mice (data not shown).
Indeed, the elevation of both 4 hr fasting and regular-feeding
blood glucose levels caused by S171A TORC2 expression alone
is resolved by the additional infection of LIPIN1 RNAi adenovirus
(Figures 6A and 6B). Consistent with the role of LIPIN1 in the
disturbance of insulin-mediated regulation of gluconeogenic
gene expression, LIPIN1 RNAi-mediated reduction of PEPCK,
G6Pase, or PGC-1a mRNA levels is much more pronounced in
feeding conditions than in 4 hr fasting conditions (Figure 6E).
Improved insulin sensitivity is also indicated by enhanced
glucose clearance in GTT assay with S171A TORC2 + LIPIN1
RNAi groups over S171A TORC2 + US mice (Figure 6C). More-
over, reduction in serine phosphorylation of AKT or FOXO1 and
induction of serine phosphorylation of PKC3 in S171A TORC2
mice are restored to control levels by additional LIPIN1 knock-
down both in basal state and insulin-injected conditions,
showing that S171A TORC2-mediated insulin resistance is
indeed partially rescued by LIPIN1 deficiency (Figures 6D and
S13). The insulin levels tend to be lower with S171A TORC2 +
LIPIN1 RNAi groups over S171A TORC2 + US mice under both
4 hr fasting and feeding conditions, reflecting the normalized gly-
cemia in this setting (Figure S14).
DISCUSSION
TORC2 has been shown to be a major regulator for hepatic
glucose production by directing transcriptional activation of glu-
coneogenic genes (Koo et al., 2005). In our study, we would now
suggest another role for this coactivator as an instigator of the
hepatic insulin resistance by activating LIPIN1. Hepatic expres-
sion of LIPIN1, a member of mammalian Mg2+-dependent
PAPs, is transcriptionally controlled by TORC2 in a CREB-
dependent manner. Hepatic LIPIN1 expression is higher in
mouse models with diet-induced or genetic obesity and insulin
resistance, conditions previously associated with constitutive
activation of TORC2 due to the impaired insulin actions (Dentin
et al., 2007; Screaton et al., 2004). We found that high-level
expression of LIPIN1 increases intracellular DAG levels and per-
turbs insulin signaling in part via a PKC3-mediated pathway. We
showed that reducing LIPIN1 expression in liver indeed improves
hepatic insulin sensitivity and normalizes hyperglycemia by
reducing hepatic DAG levels and PKC3 activity in diabetic db/
db mice. Furthermore, constitutively active TORC2-mediated
hepatic insulin resistance is partially blunted by concomitant
knockdown of LIPIN1, suggesting that TORC2-dependent
expression of LIPIN1 could indeed be responsible for this
phenomenon (see Figure 6F for a model).ell Metabolism 9, 240–251, March 4, 2009 ª2009 Elsevier Inc. 243
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Hepatic LIPIN1 Promotes FFA-Induced Insulin ResistanceFigure 2. TORC2 Activates Transcription of Hepatic LIPIN1
(A) Western blot assay showing hepatic LIPIN1 expression in mice under fed or fasted conditions.
(B) Western blot assay showing hepatic LIPIN1 expression in WT or db/db mice.
(C) RT-PCR analysis showing effect of TORC2 pathway on mRNA levels of LIPIN1 andG6Pase (top) or LIPIN family members and PEPCK (bottom) in rat primary
hepatocytes. Cells were infected with adenoviruses for GFP, TORC2, or S171A TORC2 for 48 hr and then exposed to forskolin or DMSO for 2 hr (*p < 0.05;
**p < 0.001; n = 3).
(D) Transient assays of HepG2 cells transfected with LIPIN1 luciferase constructs (*p < 0.05; **p < 0.001; n = 3).
(E) Transient assays of HepG2 cells transfected with LIPIN1 luciferase construct showing effects of expression vector for CREB dominant-negative polypeptide
(ACREB) on LIPIN1 transcription (*p < 0.05; **p < 0.001; n = 3).
(F) Chromatin immunoprecipitation showing the occupancy of TORC2 on LIPIN1 and gluconeogenic promoters in mouse primary hepatocytes. Data in (C)–(E)
represent mean ± SD.244 Cell Metabolism 9, 240–251, March 4, 2009 ª2009 Elsevier Inc.
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Hepatic LIPIN1 Promotes FFA-Induced Insulin ResistanceFigure 3. LIPIN1-Mediated DAG Production Is Linked to Hepatic Insulin Resistance
(A) Representative thin-layer chromatography analysis of formation of DAG in mouse primary hepatocytes infected with Ad-GFP, Ad-WT LIPIN1, or mutant Ad-
LIPIN1 (D712E, D714E) (*p < 0.001; n = 3).
(B) Quantitation showing relative effects of PA on insulin-dependent AKT phosphorylation from cells infected with Ad-GFP, Ad-LIPIN1, or mutant Ad-LIPIN1 as in
(C). The intensities of the bands were quantified by ImageJ (version 1.363, NIH).
(C)Western blot analysis showing effects of Ad-GFP, Ad-LIPIN1, or mutant Ad-LIPIN1 on phospho-serine and total levels of AKT and PKC3. Mouse primary hepa-
tocytes were infected with Ad-GFP, Ad-LIPIN1, or mutant Ad-LIPIN1 and then exposed to PA (50 mM) for 2 hr prior to 10 min stimulation of 100 nM insulin.
(D) Q-PCR analysis showing effect of LIPIN1 onmRNA levels of PEPCK (left) and PGC-1a (right). Cells were infected with adenoviruses for GFP, LIPIN1, or mutant
LIPIN1 for 48 hr and then cultured in the absence or in the presence of 100 mMPA (2 hr) and/or 100 nM insulin (4 hr) (*p < 0.05; **p < 0.005; n = 3). Data in (A) and (D)
represent mean ± SD.Cell Metabolism 9, 240–251, March 4, 2009 ª2009 Elsevier Inc. 245
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Hepatic LIPIN1 Promotes FFA-Induced Insulin ResistanceFigure 4. Knockdown of LIPIN1 Improves Hepatic Glucose Tolerance and Insulin Signaling in db/db Mice
(A and B) Four hour fasting glucose levels (*p < 0.01) (A) and GTT (*p < 0.05) (B) from db/db mice injected with either Ad-US (n = 4) or Ad-LIPIN1 RNAi (n = 3).
(C) Western blot analysis of total and phosphorylated forms of IR, PKC3, AKT, FOXO1, and GSK3b using extracts from 4 hr fasted mouse liver infected with either
Ad-US or Ad-LIPIN1 RNAi virus.
(D) Western blot analysis of total and phosphorylated forms of IR, PKC3, AKT, FOXO1, and GSK3b using liver extracts generated from adenovirus-infected mice
after clamp studies. (A) and (B) represent mean ± SD.In a study conducted by Finck et al., LIPIN1 seems to also
function as a coactivator for PPARa and PGC-1a to promote
fatty acid beta oxidation in livers of WT C57BL/6 mice (Finck
et al., 2006). In our study, we were unable to observe the reduc-
tion in expression of genes involved in the beta oxidation, such
as ACOX or CPT-Ia, by LIPIN1 knockdown in db/dbmouse liver
(Figures S15 and S17). Interestingly, PPARa mRNA levels are
significantly higher with LIPIN1 knockdown, perhaps compen-
sating for the reduced expression of hepatic LIPIN1 in insulin-
resistant condition that we tested in this study. Moreover, genes
involved in the lipogenesis, such as L-PK, FAS, or SCD-1, were
reciprocally decreased (Figure S16), suggesting that an equilib-
rium between fatty acid oxidation and fatty acid synthesis could
be achieved even in the absence of LIPIN1. Alternatively, the
presence of other LIPIN families in liver would partially compen-246 Cell Metabolism 9, 240–251, March 4, 2009 ª2009 Elsevier Inc.sate for the loss of LIPIN1 (Donkor et al., 2007; Reue and Zhang,
2008), although there are no significant changes in either LIPIN2
or LIPIN3 mRNA levels by LIPIN1 knockdown (Figures S16 and
S18). The relative importance between coactivator function
and PAP activity of LIPIN1 in normal or disease conditions would
be an interesting subject for future studies.
While this work was under review, two reports came out
regarding the role of LIPIN1 in triglyceride formation and VLDL
secretion in liver. In a study conducted in cultured hepatocytes,
LIPIN1 overexpression leads to increased triglyceride synthesis
and secretion, whereas siRNA-mediated knockdown of LIPIN1
selectively decreased VLDL assembly and secretion among lipo-
proteinsmeasured (Khalil et al., 2009). On the other hand, adeno-
virus-mediated overexpression of LIPIN1 in cultured fld mouse
hepatocytes or in liver of UCP-DTAmouse, a brown-fat-deficient
Cell Metabolism
Hepatic LIPIN1 Promotes FFA-Induced Insulin ResistanceFVBmousemodel that displays hyperinsulinemia (7500 pg/ml),
significantly decreased total TAG secretion, including VLDL,
showing a result somewhat inconsistent from the aforemen-
tioned study (Chen et al., 2008). To resolve differences in the
proposed functions of hepatic LIPIN1, generation of liver-
specific transgenic or knockoutmicewould be desirable to avoid
secondary effects from LIPIN1 overexpression/knockout on
other tissues, such as adipose tissue. These mouse models
would also be useful to study the longer-term effects of hepatic
LIPIN1 expression on lipidmetabolism or insulin signaling in liver.
Figure 5. Knockdown of LIPIN1 Improves Hepatic Insulin Sensitivity in db/db Mice
(A) Q-PCR analysis showing effect of Ad-US or Ad-LIPIN1 RNAi infection on hepatic expression of gluconeogenic genes in db/dbmice fasted for 4 hr. (*p < 0.05;
**p < 0.01; n = 3).
(B) Tri-, di-, and mono-acylglycerols in liver of Ad-US- and Ad-LIPIN1 RNAi-injected db/db mice (*p < 0.05; **p < 0.001; n = 3).
(C–E) Peripheral and hepatic insulin sensitivity was assessed by means of hyperinsulinemic-euglycemic clamps. Shown are hepatic glucose production (C),
skeletal muscle (gastrocnemius) glucose uptake (D), whole-body glucose uptake (E), and glycolysis and glycogen synthesis (*p < 0.05, n = 5). (A)–(E) represent
mean ± SD.Cell Metabolism 9, 240–251, March 4, 2009 ª2009 Elsevier Inc. 247
Cell Metabolism
Hepatic LIPIN1 Promotes FFA-Induced Insulin ResistanceFigure 6. LIPIN1 Knockdown Improves TORC2-Induced Hepatic Glucose Intolerance in Mice
(A–B) Four hour fasting plasma glucose levels (A) and ad libitum feeding plasma glucose levels (B) of WT C57BL/6 mice infected with Ad-GFP + Ad-US (n = 5),
Ad-S171A TORC2 + Ad-US (n = 4), or Ad-S171A TORC2 + Ad-LIPIN1i (n = 4) (*p < 0.05 for 4 hr fasting glucose and *p < 0.01 for ad libitum feeding glucose).
(C) GTT using mice as in (A). Statistically significant differences between GFP + US and S171A TORC2 + US (*p < 0.05; **p < 0.01) or S171A TORC2 + US and
S171A TORC2 + LIPIN1i (#p < 0.05; ##p < 0.01) were shown.
(D) Western blot analysis showing combined effects of Ad-S171A TORC2 and Ad-LIPIN1 RNAi on insulin singling pathway.
(E) Q-PCR analysis showing combined effects of Ad-S171A TORC2 and Ad-LIPIN1 RNAi on expression of gluconeogenic genes during 4 hr fasting or ad libitum
feeding conditions (n = 3).
(F) A proposed model of TORC2 and LIPIN1-mediated hepatic insulin resistance. Data in (A)–(C) and (E) represent mean ± SD.248 Cell Metabolism 9, 240–251, March 4, 2009 ª2009 Elsevier Inc.
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Hepatic LIPIN1 Promotes FFA-Induced Insulin ResistanceIncreased accumulation of free fatty acids in peripheral tissues
has long been regarded as a major predicament for the progres-
sion of insulin resistance (Chibalin et al., 2008; Holland et al.,
2007; Holland and Summers, 2008; Kraegen and Cooney,
2008; Savage et al., 2007). Various metabolic intermediates,
including ceramide, DAG, or their metabolites, were proposed
to be major signaling molecules for activating serine/threonine
kinases such as JNK, noncanonical PKC, S6K, or mTOR to
target IR or IR substrates to hamper insulin signaling in the cell
(Jaeschke and Davis, 2007; Nguyen et al., 2005; Samuel et al.,
2004, 2007; Um et al., 2004, 2006). A recent review from Shul-
man’s group revealed the importance of DAG as a signaling
molecule to activate PKCq in muscle or PKC3 in liver to target
either IR substrates or IR, respectively (Savage et al., 2007).
However, results from other studies implied that increase in
hepatic DAG alonemay not be a direct indication for insulin resis-
tance in liver, suggesting that the involvement of other related
mechanisms, including inflammation, is further required (Choi
et al., 2007b; Minehira et al., 2008; Monetti et al., 2007). In our
study, decreased expression of LIPIN1 reduces cellular DAG
levels that are concomitant with decreased phosphorylation of
PKC3 and enhanced tyrosine phosphorylation of IR in previously
established insulin-resistant setting, at least supporting the
hypothesis that relieving the higher hepatic DAG levels might
be beneficial to improve insulin signaling and deter the progres-
sion of type 2 diabetes. Further study will be necessary to
discern the relative contribution of various signaling cascades
that would promote insulin-resistant phenotypes in mammals.
EXPERIMENTAL PROCEDURES
Plasmids and Recombinant Adenoviruses
LIPIN1 promoter sequences were PCR-amplified from mouse genomic DNA
and inserted into the pXP2-luc vector. To generate LIPIN1 and LIPIN2 expres-
sion vectors, the coding sequences of mouse LIPIN1 and LIPIN2 were PCR-
amplified from mouse hepatic cDNA and subcloned into pcDNA3-FLAG
vector. LIPIN1 mutant (D712E, D714E) was generated using site-directed
mutagenesis (Finck et al., 2006). Adenoviruses expressing GFP only, nonspe-
cific RNAi control (US), LIPIN1, LIPIN1 RNAi, and PKC3 were generated as
described previously (Koo et al., 2005).
Animal Experiments
Seven-week-old male C57BL/6 or db/db mice were purchased from Charles
River Laboratories. Recombinant adenovirus (0.5 3 109 pfu) was delivered
by tail-vein injection to mice. To measure fasting blood glucose levels, animals
were fasted for 16 hr or 4 hr with free access to water. For GTT, mice were
fasted for 16 hr and then injected intraperitoneally with 1 g/kg (for db/db
mice) or 2 g/kg (for C57BL/6 mice) body weight of glucose (Koo et al., 2004).
Blood glucose was measured from tail-vein blood collected at the designated
times.
All procedures were approved by the Sungkyunkwan University School of
Medicine Institutional Animal Care and Use Committee (IACUC).
Quantitative PCR
Total RNA from either primary hepatocytes or liver tissue was extracted using
RNeasyMini Kit (QIAGEN). cDNAs generated by Superscript II enzyme (Invitro-
gen) were analyzed by Q-PCR using a SYBR Green PCR Kit and TP800
Thermal Cycler Dice Real Time System (TAKARA). All data were normalized
to ribosomal L32 expression.
Western Blot Analyses
Western blot analyses on 50–150 g of whole-cell extracts were performed as
described (Koo et al., 2004). LIPIN1 antibodywas fromNovus. Antisera againstCIRS1, IRS2, AKT, phospho-Ser473 AKT, GSK3b, phospho-Ser9 GSK3b,
FOXO1, phospho-Ser256 FOXO1, IRb, phospho-Tyr1162/1163 IRb, and phos-
pho-Tyrosine were purchased from Cell Signaling. Antibodies against total
PKC3 and phospho-Ser729 PKC3 were obtained from Upstate and Santa
Cruz, respectively. Antibodies against HSP90 (Santa Cruz) and a-tubulin
(Sigma) were used to assess equal loading.
Culture of Primary Hepatocytes
Primary hepatocytes were prepared from 200–300 g Sprague-Dawley rats or
8- to 10-week-old C57BL/6 mice by collagenase perfusion method as
described previously (Koo et al., 2005). Cells were plated with medium 199
supplemented by 10% FBS, 10 units/ml penicillin, 10 mg/ml streptomycin,
and 10 nM dexamethasone. After attachment, cells were infected with various
adenoviruses, indicated in figure legends, for 16 hr. Subsequently, cells were
maintained in the same media without FBS overnight and treated with 100 nM
dexamethasone and 10 mM forskolin for 2 hr with or without 100 nM insulin for
16 hr.
Transfection Assays
Human hepatoma HepG2 cells were maintained with Ham’s F12 medium sup-
plemented with 10% FBS, 10 units/ml penicillin, and 10 mg/ml streptomycin.
Each transfection was performed with 300 ng of luciferase construct, 50 ng
of b-galactosidase plasmid, and 2.5–100 ng of expression vector for
TORC2, PKA, or mutant PKA using Fugene 6 reagent, according to manufac-
turer’s instruction.
Chromatin Immunoprecipitation Assays
Nuclear isolation, cross-linking, and chromatin immunoprecipitation assays on
primary mouse hepatocyte samples were performed as described previously
(Jaeschke and Davis, 2007). Precipitated DNA fragments were analyzed by
PCR using primers against relevant mouse promoters.
Thin-Layer Chromatographic Analyses
Lipids from rat primary hepatocytes, which were labeled with 1 mCi/ml of
[3H]palmitic acid (Moravek Biochemicals, Inc.) in the serum-free medium for
18 hr, were extracted using the Bligh and Dyer method (Bligh and Dyer,
1959). DAG was separated from other phospholipids by thin-layer chromatog-
raphy using a solvent system of toluene/ether/ethanol/concentrated NH4OH
(50/30/20/0.2, v/v). DAG bands corresponding to 1,2-diacyl glycerol (Avanti
Polar Lipids) were identified with primulin, scraped, and counted using a scin-
tillation counter.
Measurement of Metabolites
Blood glucose for basal conditions and during GTT was monitored from tail-
vein blood using an automatic glucose monitor (OneTouch; LifeScan, Inc.).
Blood triglycerides and NEFA were measured by colorimetric assay kits
(Wako). Insulin was measured by Mouse Insulin ELISA Kit (U-Type; Shibayagi
Corp.). Total liver lipids were extracted with chloroform-methanol (2:1, v/v)
mixture according to Folch method (Folch et al., 1957). The extracts were dis-
solved in chloroform, and the solutions were loaded on Sep-Pak NH2 columns
(Sep-Pak Vac 6cc [500 mg] NH2 cartridge; Waters Corp.). The fractions were
separated into triacylglyceride, diacylglyceride, and monoacylglyceride (Gia-
cometti et al., 2002; Kaluzny et al., 1985). The contents were analyzed with lipid
standard (1787-1AMP, Lipid Standard, Mono-, Di-, & Triglyceride Mix;
Supelco) on HPLC-ELSD system (Evaporative Light Scattering Detector
[ELSD] ZAM 3000; Schambeck SFD GmbH) as described (Bravi et al., 2006).
Hyperinsulinemic-Euglycemic Clamp Study
Seven days prior to the hyperinsulinemic-euglycemic clamp studies,
indwelling catheters were placed into the right internal jugular vein extending
to the right atrium. After an overnight fast, [3-3H]glucose (HPLC purified; Per-
kinElmer) was infused at a rate of 0.05 mCi/min for 2 hr to assess the basal
glucose turnover. Following the basal period, hyperinsulinemic-euglycemic
clamp was conducted for 140min with a primed/continuous infusion of human
insulin (210 pmol/kg prime, 30 pmol/kg/min infusion) (Novo Nordisk;
Denmark). Blood samples (10 ml) were collected at 10–20min intervals, plasma
glucose was immediately analyzed during the clamps by a glucose oxidase
method (GM9 Analyzer; Analox Instruments; London), and 20% dextroseell Metabolism 9, 240–251, March 4, 2009 ª2009 Elsevier Inc. 249
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tions (6.7 mM). To estimate insulin-stimulated whole-body glucose fluxes,
[3-3H]glucose was infused at a rate of 0.1 mCi/min throughout the clamps,
and 2-deoxy-D-[1-14C]glucose (2-[14C]DG; PerkinElmer) was injected as
a bolus at the 85th minute of the clamp to estimate the rate of insulin-stimu-
lated tissue glucose uptake, as previously described (Choi et al., 2007a). Blood
samples (10 ml) for the measurement of plasma 3H and 14C activities were
taken at the end of the basal period and during the last 45 min of the clamp.
Glucose Flux Calculation
For the determination of plasma [3H]glucose, plasma was deproteinized with
ZnSO4 and Ba(OH)2, dried to remove [
3H]2O, resuspended in water, and
counted in scintillation fluid (Ultima Gold; PerkinElmer) on a PerkinElmer scin-
tillation counter. Rates of basal and insulin-stimulated whole-body glucose
turnover were determined as the ratio of the [3-3H]glucose infusion rate (disin-
tegrations per minute [dpm]) to the specific activity of plasma glucose (dpm/
mg) at the end of the basal period and during the final 30 min of the clamp
experiment, respectively. Hepatic glucose productionwas determined by sub-
tracting the glucose infusion rate from the total glucose appearance rate.
The plasma concentration of [3H]2O was determined by the difference
between 3H counts without and with drying. Whole-body glycolysis was calcu-
lated from the rate of increase in plasma [3H]2O concentration divided by the
specific activity of plasma [3H]glucose, as previously described (Youn and
Buchanan, 1993). Whole-body glycogen synthesis was estimated by subtract-
ing whole-body glycolysis from whole-body glucose uptake, assuming that
glycolysis and glycogen synthesis account for the majority of insulin-stimu-
lated glucose uptake (Rossetti and Giaccari, 1990).
Statistical Analyses
Results are shown as mean ± SD. The comparison of different groups was
carried out using two-tailed unpaired Student’s t test, and differences at or
under to p < 0.05 were considered statistically significant and reported as in
legends.
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